Main Article Content
To establish whether the clinical presentation of anti-cyclic citrullinated peptide (Anti-CCP)
Patients were seen in outpatient department of Lady Reading Hospital Peshawar from
February 2009 to February 2011. Participants were included in the current study if they presented within 3
months of symptom onset and fulfilled 1987 ACR criteria for (RA) in the beginning or
at some point during an 18 month follow-up. Data were collected on demographic variables and joint
symptoms (tender and swollen joint counts). C- reactive protein (CRP), erythrocyte sedimentation rate
(ESR), rheumatoid factor and Anti-CCP antibodies status were measured
110 patients were included (57 were Anti-CCP antibodies positive). The Anti-CCP antibodies
positive and negative groups were comparable in terms of demographic variables, inflammatory
markers,tender and swollen joint counts and 1987 ACR classification criteria. Rheumatoid arthritis factor
was detected more in Anti-CCP antibodies positive patients as compared with Anti-CCP antibodies
negative patients.(83.3% vs. 35.8%). There was no significant difference in the pattern of joint
involvement, except for an increased prevalence of knee joint swelling in Anti-CCP antibodies positive
patients (56.1% vs.17.5%).
Patients with and without Anti-CCP antibodies present in a similar way, even within three
months of clinically apparent disease that eventually develops into Rheumatoid arthritis.
antibodies and negative disease are distinct at the earliest clinically apparent phase of disease.
Work published in JPMI is licensed under a
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.